|
|
| Titles |
1993 Canadian Journal of Psychiatry Zoloft |
| Related Item |
|
| Genre |
medicine |
| Genre |
medicines (psychiatric) |
| Identifier |
cjp1993aug_sep_oct_nov_dec24 |
| Note |
Now on the Ontario Drug Benefit Formulary. Zoloft delivers first-line SSRI antidepressant efficacy with virtually no agitation or sedation. Zoloft (sertraline HCl/Pfizer) allows your patients to enjoy the benefits of antidepressant therapy with little risk of agitation, insomnia, or sedation. While relieving the symptoms of depression with efficacy comparable to imipramine and amitriptyline, Zoloft has virtually no detrimental effect on psychomotor and cognitive performance that can interfere with daytime functioning - and may results in non-compliance to therapy. Favourable safety profile. While tricyclics have significant cardiovascular effects at therapeutic doses, Zoloft has few cardiac effects and is not associated with significant ECG abnormalities. Favourable pharmacokinetic profile. Zoloft has no intrinsic anti-cholinergic activity to cause the troubling side effects traditionally associated with antidepressant therapy. And Zoloft produces no clinically active metabolites, has a significantly shorter half-life then fluoxetine, and a low risk of drug interaction. In fact, Zoloft can usually be prescribed for the elderly with no dosage adjustment. Zolost antidepressant efficacy with few side effects to compromise your patient's recovery. |
| Abstract |
Sertraline HCI, Pfizer, A woman, with a neutral expression, working on some sort of art project. She is holding a clear flower in her hand with a flame pointed toward the object, as she is holding a glass rod to the flame. |
